Effect of silibinin on endothelial dysfunction and ADMA levels in obese diabetic mice

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Li Volti, Giovanni ^a,b   Salomone, Salvatore ^a   Sorrenti, Valeria ^a   Mangiameli, Andrea ^a   Urso, Vincenzo ^a   Siarkos, Ilias ^a   Galvano, Fabio ^a   Salamone, Federico ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b San Donato Institute   (Italy)

Author keywords

ADMA; Db db; Diabetes; Endothelial dysfunction; Silibinin; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; POLYPHENOL; SILIBININ; ANTIOXIDANT; ARGININE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; SILYMARIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD LEVEL; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; INSULIN RESISTANCE; LIVER LEVEL; MALE; MOUSE; NONHUMAN; OBESITY; VASODILATATION; ANIMAL; DISEASE MODEL; DRUG EFFECT; LIVER; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ANIMALS; ANTIOXIDANTS; AORTA; ARGININE; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, OBESE; NITROPRUSSIDE; OBESITY; PHENYLEPHRINE; SILYMARIN; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 79960275495     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-62     Document Type: Article

References (33)

1. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113-1132. 10.1016/j.jacc.2010.05.034, 20863953.
2. Reriani MK, Lerman LO, Lerman A. Endothelial function as a functional expression of cardiovascular risk factors. Biomark Med 2010, 4:351-360. 10.2217/bmm.10.61, 2911781, 20550469.
3. Sima AV, Stancu CS, Simionescu M. Vascular endothelium in atherosclerosis. Cell Tissue Res 2009, 335:191-203. 10.1007/s00441-008-0678-5, 18797930.
4. Manach C, Mazur A, Scalbert A. Polyphenols and prevention of cardiovascular diseases. Curr Opin Lipidol 2005, 16:77-84. 10.1097/00041433-200502000-00013, 15650567.
5. Wang YK, Hong YJ, Huang ZQ. Protective effects of silybin on human umbilical vein endothelial cell injury induced by H2O2 in vitro. Vascul Pharmacol 2005, 43:198-206. 10.1016/j.vph.2005.06.002, 16111923.
6. Elahi MM, Kong YX, Matata BM. Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev 2009, 2:259-269. 10.4161/oxim.2.5.9441, 2835914, 20716913.
7. Jin JS, D'Alecy LG. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol 1996, 28:439-446. 10.1097/00005344-199609000-00014, 8877592.
8. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
9. Nanayakkara PW, Teerlink T, Stehouwer CD, Allajar D, Spijkerman A, Schalkwijk C, ter Wee PM, van Guldener C. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int 2005, 68:2230-2236. 10.1111/j.1523-1755.2005.00680.x, 16221223.
10. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997, 95:2068-2074.
11. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003, 4:33-40.
12. Wilcken DE, Sim AS, Wang J, Wang XL. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab 2007, 91:309-317. 10.1016/j.ymgme.2007.04.017, 17560156.
13. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003, 22:17-22.
14. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 1995, 117:237-238. 10.1093/jb/117.2.237, 7608105.
15. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000, 20:2039-2044. 10.1161/01.ATV.20.9.2039, 10978246.
16. Nash DT. Insulin resistance, ADMA levels, and cardiovascular disease. JAMA 2002, 20;287:1451-1452.
17. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, Wu G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006, 49:351-359. 10.1007/s00125-005-0066-6, 16369774.
18. McLaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, Tsao PS. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006, 91:1896-1900. 10.1210/jc.2005-1441, 16507636.
19. Kamata K, Kojima S. Characteristics of contractile responses of aorta to norepinephrine in db/db mice. Res Commun Mol Pathol Pharmacol 1997, 96:319-328.
20. Piercy V, Taylor SG. A comparison of spasmogenic and relaxant responses in aortae from C57/BL/KsJ diabetic mice with those from their non-diabetic litter mates. Pharmacology 1998, 56:267-275. 10.1159/000028208, 9597695.
21. Lagaud GJ, Masih-Khan E, Kai S, van Breemen C, Dube GP. Influence of type II diabetes on arterial tone and endothelial function in murine mesenteric resistance arteries. J Vasc Res 2001, 38:578-589. 10.1159/000051094, 11740157.
22. Elmi S, Sallam NA, Rahman MM, Teng X, Hunter AL, Moien-Afshari F, Khazaei M, Granville DJ, Laher I. Sulfaphenazole treatment restores endothelium-dependent vasodilation in diabetic mice. Vascul Pharmacol 2008, 48:1-8. 10.1016/j.vph.2007.09.001, 17974492.
23. Miike T, Kunishiro K, Kanda M, Azukizawa S, Kurahashi K, Shirahase H. Impairment of endothelium-dependent ACh-induced relaxation in aorta of diabetic db/db mice--possible dysfunction of receptor and/or receptor-G protein coupling. Naunyn Schmiedebergs Arch Pharmacol 2008, 377:401-410. 10.1007/s00210-008-0261-3, 18228001.
24. Nuno DW, Harrod JS, Lamping KG. Sex-dependent differences in Rho activation contribute to contractile dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2009, 297:H1469-H1477. 10.1152/ajpheart.00407.2009, 19666843.
25. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8:e1000412. 10.1371/journal.pbio.1000412, 2893951, 20613859.
26. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977, 41:19-26.
27. Antoniades C, Demosthenous M, Tousoulis D, Antonopoulos AS, Vlachopoulos C, Toutouza M, Marinou K, Bakogiannis C, Mavragani K, Lazaros G, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011, 58:93-98. 10.1161/HYPERTENSIONAHA.110.168245, 21518967.
28. Sibal L, Agarwal SC, Schwedhelm E, Luneburg N, Boger RH, Home PD. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol 2009, 8:27. 10.1186/1475-2840-8-27, 2698883, 19486510.
29. Guigas B, Naboulsi R, Villanueva GR, Taleux N, Lopez-Novoa JM, Leverve XM, El-Mir MY. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perfused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase. Cell Physiol Biochem 2007, 20:925-934. 10.1159/000110453, 17982275.
30. Anderssohn M, Schwedhelm E, Luneburg N, Vasan RS, Boger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010, 7:105-118. 10.1177/1479164110366053, 20382774.
31. Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011, 10:16. 10.1186/1475-2840-10-16, 3050685, 21303562.
32. Siroen MP, van der Sijp JR, Teerlink T, van SC, Nijveldt RJ, van Leeuwen PA. The human liver clears both asymmetric and symmetric dimethylarginine. Hepatology 2005, 41:559-565. 10.1002/hep.20579, 15726655.
33. Carello KA, Whitesall SE, Lloyd MC, Billecke SS, D'Alecy LG. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol 2006, 290:H209-H216.